Press Releases

Investors

E-mail Alerts

Mar 7, 2018

Viking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Mar 6, 2018

Viking Therapeutics to Present at Upcoming Investor Conferences

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Feb 28, 2018

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2017 on March 7, 2018

Conference Call Scheduled for Wednesday, March 7 at 4:30 p.m. Eastern Time

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today...
Feb 7, 2018

Viking Therapeutics to Present at 2018 BIO CEO & Investor Conference

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Feb 6, 2018

Viking Therapeutics Announces Closing of Public Offering of Common Stock

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...